The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Filgrastim Biosimilars Market Evolve From 2026 To 2030?
The filgrastim biosimilars market has experienced rapid expansion over recent years. This market is projected to expand from $1.19 billion in 2025 to $1.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Historically, this growth can be ascribed to several factors, including the elevated cost of originator filgrastim, the rising incidence of cancer and blood disorders, restricted access to biologics in developing areas, expanding hospital infrastructure, and the timely approval of biosimilars by regulatory bodies.
The filgrastim biosimilars market is projected to expand significantly over the coming years. This market is anticipated to reach a value of $2.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. Key factors driving this expansion during the forecast period include the introduction of advanced filgrastim biosimilars, an increase in contract manufacturing collaborations, greater uptake in the management of chronic and autoimmune conditions, enhanced government backing and favorable reimbursement frameworks, and the evolution of distribution and delivery systems focused on patients. Significant developments expected in this timeframe involve the growing use of filgrastim biosimilars in cancer and blood disorder therapies, the enlargement of contract manufacturing organizations dedicated to biosimilar production, a rise in the utilization of internal vertically integrated manufacturing sites, a stronger inclination towards hospital and retail pharmacy distribution routes, and a strategic emphasis on affordable biologics and market penetration in developing regions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp
What Major Drivers Are Influencing Demand In The Filgrastim Biosimilars Market?
The increasing occurrence of cancer is projected to propel the expansion of the filgrastim biosimilars market in the future. Cancer encompasses a range of illnesses characterized by the unchecked proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that impair typical cellular control. The rising rate of cancer diagnoses can be partially attributed to the aging global population, as extended lifespans correlate with an elevated probability of developing cancer-causing genetic mutations. Filgrastim biosimilars assist individuals with cancer by stimulating the generation of white blood cells, thereby lowering the danger of neutropenia caused by chemotherapy, and facilitating more secure and uninterrupted cancer therapies. For example, data from October 2025, reported by the National Health Service (NHS), a UK-based government health agency, indicated 354,820 new cancer diagnoses in 2023, averaging 972 cases daily, which represented an increase of 8,605 compared to 2022. Consequently, the growing prevalence of cancer is actively driving the filgrastim biosimilars market.
Which Segment Areas Are Covered In The Filgrastim Biosimilars Market Analysis?
The filgrastim biosimilars market covered in this report is segmented –
1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing
2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services
What Key Developments And Trends Are Impacting The Filgrastim Biosimilars Market?
Prominent companies in the filgrastim biosimilar market are creating innovative products utilizing advanced technologies, such as recombinant DNA technology, for biosimilar manufacturing. Recombinant DNA technology is a procedure characterized by the formation of hybrid or chimeric DNA through the insertion of an external sequence into an organism’s DNA. For example, Amneal Pharmaceuticals, a US-based pharmaceutical firm, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States in May 2023. This product, a biosimilar to Amgen’s NEULASTA, is indicated for managing and preventing febrile neutropenia. It encourages the proliferation and specialization of neutrophils originating from specific precursor cells, initiates their maturation, and enhances the vitality and performance of developed neutrophils, leading to increases in neutrophil counts proportional to the dosage. The release of Fylnetra contributes to the next generation of affordable medications and expands access for patients, providers, and payors alike.
Which Global Companies Are Actively Competing In The Filgrastim Biosimilars Market?
Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.
Read the full filgrastim biosimilars market report here:
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report
Which Region Shows The Strongest Potential For Future Growth In The Filgrastim Biosimilars Market?
North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Filgrastim Biosimilars Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp
Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company
Neutropenia Biologic Drug Treatments Market Report 2026
G Csf Market Report 2026
https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report
Pegfilgrastim Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model